BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Liu X, Long C, Xiong Q, Chen C, Ma J, Su Y, Hong K. Association of angiotensin converting enzyme inhibitors and angiotensin II receptor blockers with risk of COVID-19, inflammation level, severity, and death in patients with COVID-19: A rapid systematic review and meta-analysis. Clin Cardiol 2020. [PMID: 32757246 DOI: 10.1002/clc.23421] [Cited by in Crossref: 23] [Cited by in F6Publishing: 24] [Article Influence: 11.5] [Reference Citation Analysis]
Number Citing Articles
1 Sriram K, Loomba R, Insel PA. Targeting the renin-angiotensin signaling pathway in COVID-19: Unanswered questions, opportunities, and challenges. Proc Natl Acad Sci U S A 2020;117:29274-82. [PMID: 33203679 DOI: 10.1073/pnas.2009875117] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
2 Ferrari F, Martins VM, Fuchs FD, Stein R. Renin-Angiotensin-Aldosterone System Inhibitors in COVID-19: A Review. Clinics (Sao Paulo) 2021;76:e2342. [PMID: 33852652 DOI: 10.6061/clinics/2021/e2342] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Kebria MM, Milan PB, Peyravian N, Kiani J, Khatibi S, Mozafari M. Stem cell therapy for COVID-19 pneumonia. Mol Biomed 2022;3:6. [PMID: 35174448 DOI: 10.1186/s43556-021-00067-8] [Reference Citation Analysis]
4 Perico L, Benigni A, Remuzzi G. Angiotensin-converting enzyme 2: from a vasoactive peptide to the gatekeeper of a global pandemic. Curr Opin Nephrol Hypertens 2021;30:252-63. [PMID: 33395036 DOI: 10.1097/MNH.0000000000000692] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Liu D, Zeng X, Ding Z, Lv F, Mehta JL, Wang X. Adverse Cardiovascular Effects of Anti-COVID-19 Drugs. Front Pharmacol 2021;12:699949. [PMID: 34512335 DOI: 10.3389/fphar.2021.699949] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Li M, Wang Y, Ndiwane N, Orner MB, Palacios N, Mittler B, Berlowitz D, Kazis LE, Xia W. The association of COVID-19 occurrence and severity with the use of angiotensin converting enzyme inhibitors or angiotensin-II receptor blockers in patients with hypertension. PLoS One 2021;16:e0248652. [PMID: 33735262 DOI: 10.1371/journal.pone.0248652] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
7 Salvador P, Oliveira P, Costa T, Fidalgo M, Neto R, Silva ML, Figueiredo C, Afreixo V, Gregório T, Malheiro L. Clinical Features and Prognostic Factors of 245 Portuguese Patients Hospitalized With COVID-19. Cureus 2021;13:e13687. [PMID: 33833912 DOI: 10.7759/cureus.13687] [Reference Citation Analysis]
8 Reddy PR, Samavedam S, Aluru N, Boggu R. Comparison of Severity of COVID-19 Infection among Patients Using RAAS Inhibitors and Non-RAAS Inhibitors. Indian J Crit Care Med 2021;25:366-8. [PMID: 34045800 DOI: 10.5005/jp-journals-10071-23774] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
9 Li Z, Shao W, Zhang J, Ma J, Huang S, Yu P, Zhu W, Liu X. Prevalence of Atrial Fibrillation and Associated Mortality Among Hospitalized Patients With COVID-19: A Systematic Review and Meta-Analysis. Front Cardiovasc Med 2021;8:720129. [PMID: 34722658 DOI: 10.3389/fcvm.2021.720129] [Reference Citation Analysis]
10 Kriszta G, Kriszta Z, Váncsa S, Hegyi PJ, Frim L, Erőss B, Hegyi P, Pethő G, Pintér E. Effects of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers on Angiotensin-Converting Enzyme 2 Levels: A Comprehensive Analysis Based on Animal Studies. Front Pharmacol 2021;12:619524. [PMID: 33762942 DOI: 10.3389/fphar.2021.619524] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
11 Mackey K, Kansagara D, Vela K. Update Alert 4: Risks and Impact of Angiotensin-Converting Enzyme Inhibitors or Angiotensin-Receptor Blockers on SARS-CoV-2 Infection in Adults. Ann Intern Med 2020;173:W147-8. [PMID: 32956599 DOI: 10.7326/L20-1177] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
12 Loader J, Taylor FC, Lampa E, Sundström J. Renin-Angiotensin Aldosterone System Inhibitors and COVID-19: A Systematic Review and Meta-Analysis Revealing Critical Bias Across a Body of Observational Research. J Am Heart Assoc 2022;:e025289. [PMID: 35624081 DOI: 10.1161/JAHA.122.025289] [Reference Citation Analysis]
13 Zhang Q, Ling S, Hu K, Liu J, Xu J. Role of the renin-angiotensin system in NETosis in the coronavirus disease 2019 (COVID-19). Biomedicine & Pharmacotherapy 2022;148:112718. [DOI: 10.1016/j.biopha.2022.112718] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
14 Rizk JG, Wenziger C, Tran D, Hashemi L, Moradi H, Streja E, Ahluwalia A. Angiotensin-Converting Enzyme Inhibitor and Angiotensin Receptor Blocker Use Associated with Reduced Mortality and Other Disease Outcomes in US Veterans with COVID-19. Drugs 2021. [PMID: 34914085 DOI: 10.1007/s40265-021-01639-2] [Reference Citation Analysis]
15 Chueh TI, Zheng CM, Hou YC, Lu KC. Novel Evidence of Acute Kidney Injury in COVID-19. J Clin Med 2020;9:E3547. [PMID: 33153216 DOI: 10.3390/jcm9113547] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 5.0] [Reference Citation Analysis]
16 Liu X, Long C, Xiong Q, Chen C, Ma J, Su Y, Hong K. Re: Is there a difference in the effect between the angiotensin-converting enzyme inhibitor and angiotensin-receptor blocker on the COVID-19? Clin Cardiol 2021;44:7-8. [PMID: 33180964 DOI: 10.1002/clc.23473] [Reference Citation Analysis]
17 Legrand M, Bell S, Forni L, Joannidis M, Koyner JL, Liu K, Cantaluppi V. Pathophysiology of COVID-19-associated acute kidney injury. Nat Rev Nephrol 2021. [PMID: 34226718 DOI: 10.1038/s41581-021-00452-0] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
18 Harris S, Ruan Y, Wild SH, Wargny M, Hadjadj S, Delasalle B, Saignes M, Ryder RE, Field BCT, Narendran P, Zaccardi F, Wilmot EG, Vlacho B, Llauradó G, Mauricio D, Nagi D, Patel D, Várnai KA, Davies J, Gourdy P, Cariou B, Rea R, Khunti K; CORONADO, the ABCD COVID-19 diabetes national audit and HM Hospitales investigators. Association of statin and/or renin-angiotensin-aldosterone system modulating therapy with mortality in adults with diabetes admitted to hospital with COVID-19: A retrospective multicentre European study. Diabetes Metab Syndr 2022;16:102484. [PMID: 35472685 DOI: 10.1016/j.dsx.2022.102484] [Reference Citation Analysis]
19 Ajmera V, Thompson WK, Smith DM, Malhotra A, Mehta RL, Tolia V, Yin J, Sriram K, Insel PA, Collier S, Richards L, Loomba R. RAMIC: Design of a randomized, double-blind, placebo-controlled trial to evaluate the efficacy of ramipril in patients with COVID-19. Contemp Clin Trials 2021;103:106330. [PMID: 33631357 DOI: 10.1016/j.cct.2021.106330] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
20 Gong J, Sun Y, Xie L. ACEI/ARB Drug Therapy in COVID-19 Patients: Yes Or No? J Transl Int Med 2021;9:8-11. [PMID: 33850795 DOI: 10.2478/jtim-2021-0011] [Reference Citation Analysis]
21 Choksi TT, Zhang H, Chen T, Malhotra N. Outcomes of Hospitalized COVID-19 Patients Receiving Renin Angiotensin System Blockers and Calcium Channel Blockers. Am J Nephrol 2021;52:250-60. [PMID: 33827074 DOI: 10.1159/000515232] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 8.0] [Reference Citation Analysis]
22 Gupta N, Settle L, Brown BR, Armaignac DL, Baram M, Perkins NE, Kaufman M, Melamed RR, Christie AB, Danesh VC, Denson JL, Cheruku SR, Boman K, Bansal V, Kumar VK, Walkey AJ, Domecq JP, Kashyap R, Aston CE; Society of Critical Care Medicine Discovery Viral Infection and Respiratory Illness Universal Study (VIRUS): COVID-19 Registry Investigator Group. Association of Renin Angiotensin Aldosterone System Inhibitors and Outcomes of Hospitalized Patients With COVID-19. Crit Care Med 2022. [PMID: 35894609 DOI: 10.1097/CCM.0000000000005627] [Reference Citation Analysis]
23 Gaspar P, Parreira I, Antunes Meireles P, Bessa F, Dias Silva V, Abrantes AM, Pais de Lacerda A, Mota C. The Effect of Chronic and Inhospital Exposure to Renin-Angiotensin System Inhibitors on the Outcome and Inflammatory State of Coronavirus Disease 2019 Adult Inpatients. Int J Hypertens 2021;2021:5517441. [PMID: 33824762 DOI: 10.1155/2021/5517441] [Reference Citation Analysis]
24 Chen J, Mei K, Deng C. Is there a difference in the effect between the ACEI and ARB on COVID-19? Clin Cardiol 2021;44:5-6. [PMID: 33205837 DOI: 10.1002/clc.23474] [Reference Citation Analysis]
25 Jansen van Vuren E, Steyn SF, Brink CB, Möller M, Viljoen FP, Harvey BH. The neuropsychiatric manifestations of COVID-19: Interactions with psychiatric illness and pharmacological treatment. Biomed Pharmacother 2021;135:111200. [PMID: 33421734 DOI: 10.1016/j.biopha.2020.111200] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 14.0] [Reference Citation Analysis]
26 Batiha GE, Gari A, Elshony N, Shaheen HM, Abubakar MB, Adeyemi SB, Al-Kuraishy HM. Hypertension and its management in COVID-19 patients: The assorted view. Int J Cardiol Cardiovasc Risk Prev 2021;11:200121. [PMID: 34806090 DOI: 10.1016/j.ijcrp.2021.200121] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 6.0] [Reference Citation Analysis]
27 Hasan SS, Kow CS, Hadi MA, Zaidi STR, Merchant HA. Mortality and Disease Severity Among COVID-19 Patients Receiving Renin-Angiotensin System Inhibitors: A Systematic Review and Meta-analysis. Am J Cardiovasc Drugs 2020;20:571-90. [PMID: 32918209 DOI: 10.1007/s40256-020-00439-5] [Cited by in Crossref: 21] [Cited by in F6Publishing: 15] [Article Influence: 10.5] [Reference Citation Analysis]
28 Wan Q, Zhou Y, Zhu W, Liu X. Sex-Specific Exposure-Effect Relationship Between Physical Activity and Incident Atrial Fibrillation in the General Population: A Dose-Response Meta-Analysis of 16 Prospective Studies. Front Cardiovasc Med 2021;8:710071. [PMID: 34631817 DOI: 10.3389/fcvm.2021.710071] [Reference Citation Analysis]
29 Liu X, Long C, Xiong Q, Chen C, Ma J, Su Y, Hong K. Association of angiotensin converting enzyme inhibitors and angiotensin II receptor blockers with risk of COVID-19, inflammation level, severity, and death in patients with COVID-19: A rapid systematic review and meta-analysis. Clin Cardiol 2020. [PMID: 32757246 DOI: 10.1002/clc.23421] [Cited by in Crossref: 23] [Cited by in F6Publishing: 24] [Article Influence: 11.5] [Reference Citation Analysis]
30 Gupta N, Patel K, Gupta R. The other possible mechanism of the benefits of RAAS inhibition in the athogenesis of COVID-19. Clin Cardiol 2020;43:1349. [PMID: 33174213 DOI: 10.1002/clc.23494] [Reference Citation Analysis]
31 Fu L, Liu X, Su Y, Ma J, Hong K. Prevalence and impact of cardiac injury on COVID-19: A systematic review and meta-analysis. Clin Cardiol 2021;44:276-83. [PMID: 33382482 DOI: 10.1002/clc.23540] [Cited by in Crossref: 2] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
32 Prieto Santamaría L, Díaz Uzquiano M, Ugarte Carro E, Ortiz-Roldán N, Pérez Gallardo Y, Rodríguez-González A. Integrating heterogeneous data to facilitate COVID-19 drug repurposing. Drug Discov Today 2021:S1359-6446(21)00438-4. [PMID: 34666181 DOI: 10.1016/j.drudis.2021.10.002] [Cited by in Crossref: 3] [Article Influence: 3.0] [Reference Citation Analysis]
33 Matucci-Cerinic M, Hughes M, Taliani G, Kahaleh B. Similarities between COVID-19 and systemic sclerosis early vasculopathy: A "viral" challenge for future research in scleroderma. Autoimmun Rev 2021;20:102899. [PMID: 34274540 DOI: 10.1016/j.autrev.2021.102899] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
34 Jeffery MM, Oliveira J E Silva L, Bellolio F, Garovic VD, Dempsey TM, Limper A, Cummins NW. Association of outpatient use of renin-angiotensin-aldosterone system blockers on outcomes of acute respiratory illness during the COVID-19 pandemic: a cohort study. BMJ Open 2022;12:e060305. [PMID: 35793915 DOI: 10.1136/bmjopen-2021-060305] [Reference Citation Analysis]
35 Lee T, Cau A, Cheng MP, Levin A, Lee TC, Vinh DC, Lamontagne F, Singer J, Walley KR, Murthy S, Patrick D, Rewa OG, Winston BW, Marshall J, Boyd J, Tran K, Kalil AC, Mcculoh R, Fowler R, Luther JM, Russell JA; ARBs CORONA. Angiotensin Receptor Blockers and Angiotensin-Converting Enzyme Inhibitors in COVID-19: Meta-analysis/Meta-regression Adjusted for Confounding Factors. CJC Open 2021;3:965-75. [PMID: 33842874 DOI: 10.1016/j.cjco.2021.03.001] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]